An increase in the total bilirubin level was observed in 11 (45.8%) patients, anorexia was noted in 10 (41.7%) patients, anemia in 9 (37.5%) patients, fatigue and weight loss in 8 (33.3%) patients, thrombocytopenia in 7 (29.2%) patients, leukopenia, AST level increase and hyperpigmentation in 6 (25.0%) patients, rash/desquamation in 5 (20.8%) patients, ALT level increase in 4 (16.7%) patients, nausea in 3 (12.5%) patients, and vomiting in 2 (8.3%) patients. This evidence concerns the gene GPT and anemia.